AI Terminal
Heidelberg Pharma AG
Regulatory Filings • Nov 13, 2017
201_rns_2017-11-13_ebc468d1-08c1-48b2-ab5b-a066ccb185ee.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 13 November 2017 16:48
Heidelberg Pharma AG announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting
DGAP-News: Heidelberg Pharma AG / Key word(s): Study results
13.11.2017 / 16:48
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Heidelberg Pharma AG announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting
– ATAC efficacy evaluated in multiple myeloma cells
– Promising top-line results with HDP-101 available
– Research results to be presented at American Society of Hematology (ASH) Annual Meeting in early December
Ladenburg, Germany, 13 November 2017 – Heidelberg Pharma AG (ISIN DE000A11QVV0 / WKN A11QVV / WL6) today announced that it will present top-line results from a research collaboration with Heidelberg University and the German Cancer Research Center (DKFZ) led by Dr. Marc-Steffen Raab at the 59th ASH (American Society of Hematology) Annual Meeting, the leading conference for hematologic diseases, taking place from 9 to 12 December 2017 in Atlanta, GA, USA.
The collaboration evaluated the efficacy of the development candidate HDP-101 on multiple myeloma cells isolated from patients. HDP-101 consists of a BCMA antibody, a specific linker and the toxin Amanitin. BCMA (B-cell maturation antigen) is a surface protein that is selectively expressed in multiple myeloma cells and to which the selected antibody specifically binds. In the jointly conducted preclinical study, non-dividing cancer cells taken from multiple myeloma patients were examined with HDP-101. A strong cytotoxic effect was observed including at very low doses, even in cancer cells with a low concentration of BCMA antigens. No toxicity was observed on non-BCMA expressing control cells. This is the first time that the efficacy of Amanitin on cancer cells taken from human patients was demonstrated.
Antibody drug conjugates (ADCs) with Amanitin represent a novel therapeutic approach for treating multiple myeloma. The toxin’s biological mode of action could break through drug resistance and improve the prognosis of patients. Heidelberg Pharma expects to initiate a clinical trial with HDP-101 by the end of 2018.
Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma AG, commented: “This preclinical study in multiple myeloma carried out jointly with Heidelberg University and the DKFZ demonstrates the effect of our candidate HDP-101 on tumor cells isolated directly from patients, providing us with further important support of the efficacy of our first proprietary ATAC candidate HDP-101, which is of major importance to us. We are delighted that the results will be presented at such an important event as the ASH Annual Meeting.”
Presentation details:
Poster : 3070 Preclinical Evaluation of HDP-101, a Novel Anti-Bcma Antibody-Drug Conjugate, in Multiple Myeloma
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Date : Sunday, 10 December 2017
Time: 6:00 – 8:00 pm
Place: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
The abstract is available online and will also be published in a special issue of “Blood” on 8 December 2017.
About Heidelberg Pharma AG
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON (R) and REDECTANE (R) , while RENCAREX (R) is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com .
| Contact Heidelberg Pharma AG Sylvia Wimmer Tel.: +49 89 41 31 38-29 Email: investors[at]hdpharma.com Schriesheimer Str. 101, 68526 Ladenburg |
IR/PR support MC Services AG Katja Arnold (CIRO) Managing Director & Partner Tel.: +49 89-210 228-40 Email: katja.arnold[at]mc-services.eu |
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
13.11.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Heidelberg Pharma AG |
| Schriesheimer Str. 101 | |
| 68526 Ladenburg | |
| Germany | |
| Phone: | +49 (0)89 41 31 38 – 0 |
| Fax: | +49 (0)89 41 31 38 – 99 |
| E-mail: | [email protected] |
| Internet: | www.heidelberg-pharma.com |
| ISIN: | DE000A11QVV0 |
| WKN: | A11QVV |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| End of News | DGAP News Service |